Tango Therapeutics, Inc. (TNGX) Financial Analysis & Valuation | Quarter Chart
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine pho... more
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $3.78B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Malte Peters |
| IPO Date | 2020-09-03 | CAGR | 16.74% |
| Employees | 137 | Website | www.tangotx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
TNGX chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $3.90B | P/E | -28 | Forward P/E | -13.79 | PEG | — |
| P/S | 3.52 | P/B | 0.17 | P/CF | -1.21 | P/FCF | -1.32 |
| Sales | $53.81M | Sales 1Y | 121.47% | Sales 3Y | 59.7% | Sales 5Y | 140.02% |
| EPS | $-0.83 | EPS 1Y | -35.61% | EPS 3Y | -27.35% | EPS 5Y | 38.48% |
| Sales QoQ | — | EPS QoQ | 15.62% | Sales QoQ Avg | — | EPS QoQ Avg | -108% |
| Gross Margin | 98.25% | Operating Margin | -253.38% | Profit Margin | -229.92% | ROCE | -12.94% |
| ROA | -12% | ROE | -26% | Altman Z Score | 47.53 | Piotroski Score | 2 |
| Current Ratio | 50.82 | Quick Ratio | 50.82 | Cash Ratio | 17.02 | Op. CF Ratio | -1.95 |
| Debt/Equity | 0.03 | Debt/Assets | 0.03 | Lt Debt/Equity | 0.03 | Lt Debt/Cap. | 0.03 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.05 | Receivables Turnover | — |
| Enterprise Value | $3.90B | P/E Ratio | -28 |
| Forward P/E | -13.79 | PEG Ratio | — |
| P/S Ratio | 3.52 | P/B Ratio | 0.17 |
| P/CF Ratio | -1.21 | P/FCF Ratio | -1.32 |
| EPS | $-0.83 | EPS Growth 1Y | -35.61% |
| EPS Growth 3Y | -27.35% | EPS Growth 5Y | 38.48% |
| Revenue Growth 1Y | 121.47% | Gross Margin | 98.25% |
| Operating Margin | -253.38% | Profit Margin | -229.92% |
| ROE | -26% | ROA | -12% |
| ROCE | -12.94% | Current Ratio | 50.82 |
| Quick Ratio | 50.82 | Cash Ratio | 17.02 |
| Debt/Equity | 0.03 | Interest Coverage | — |
| Altman Z Score | 47.53 | Piotroski Score | 2 |
Tango Therapeutics, Inc. (TNGX) valuation & financials
Tango Therapeutics, Inc. (TNGX) has a market capitalization of $3.78B and trades at a price-to-earnings ratio of -28.0. It operates in the Healthcare sector (Biotechnology).
Tango Therapeutics, Inc.'s revenue grew +121.5% over the last year.
Tango Therapeutics, Inc.'s next earnings report is scheduled for November 3, 2026 before market open (provider scheduled date); analysts estimate EPS of $-0.34. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)